The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and preliminary efficacy of ivaltinostat, an HDAC inhibitor, plus capecitabine in patients with pretreated metastatic pancreatic adenocarcinoma (mPDAC): Results of a phase Ib study.
 
Christos Fountzilas
Research Funding - Amgen (Inst); Aravive (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals (Inst); Biomea Fusion (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Corcept Therapeutics (Inst); CrystalGenomics (Inst); Dragonfly Therapeutics (Inst); ERYTECH Pharma (Inst); Ipsen (Inst); Kadmon (Inst); Legend Biotech USA Inc (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst); Sanofi (Inst); Seagen (Inst); Taiho Oncology (Inst); TransThera Biosciences (Inst); Valar Labs (Inst)
Travel, Accommodations, Expenses - CG Pharmaceuticals
 
Andrew Ko
Honoraria - Medscape; MJH Life Sciences; Research to Practice
Consulting or Advisory Role - AADi; Arcus Biosciences; Eisai; FibroGen; Genentech; GRAIL; Merus; Roche/Genentech
Research Funding - AbGenomics International (Inst); Apexigen (Inst); Astellas Pharma (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CrystalGenomics (Inst); Genentech/Roche (Inst); Leap Therapeutics (Inst); Merck (Inst); Verastem (Inst)
 
Erkut Borazanci
Consulting or Advisory Role - BPGbio; ClearNote Health; Conjupro Biotherapeutics; Conjupro Biotherapeutics; Elevation Oncology; NanOlogy; Qurient
Research Funding - BioNTech (Inst); Biosplice (Inst); Bristol-Myers Squibb (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo (Inst); Helix BioPharma (Inst); Idera (Inst); Lilly (Inst); Merck (Inst); Minneamrita Therapeutics (Inst); Pharmacyclics (Inst)
 
James D'Olimpio
No Relationships to Disclose
 
Joel Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals; Trumvira
Consulting or Advisory Role - Astellas Pharma; BeiGene; Bristol-Myers Squibb/Medarex; Galvanize Therapeutics; IgM Biosciences; MBQ Pharma; Taiho Pharmaceutical
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Amgen (Inst); Bold Therapeutics (Inst); Camurus (Inst); Cardiff Oncology (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Janssen Oncology (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neogene Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Regeneron (Inst); Revolution Medicines (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst); Xilio Therapeutics (Inst)
 
Shou-Ching Tang
No Relationships to Disclose
 
Anthony Shields
Consulting or Advisory Role - Caris Life Sciences; Cogent Biosciences; ImaginAb; Legend Biotech
Speakers' Bureau - Caris Life Sciences
Research Funding - Abbisko Therapeutics (Inst); Alkermes; Amal Therapeutics (Inst); Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; Gritstone Bio (Inst); H3 Biomedicine; Halozyme; Hutchison China Meditech; IconOVir Bio (Inst); ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Nuvation Bio (Inst); Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Sorrento Therapeutics (Inst); SQZ Biotechnology (Inst); Taiho Pharmaceutical; Telix Pharmaceuticals; TopAlliance BioSciences Inc (Inst); Torque (Inst); Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Mohamad Salkeni
Employment - Next Oncology; Virginia Cancer Specialists
Stock and Other Ownership Interests - Next Oncology
Honoraria - Healthcasts
Research Funding - 1ST Biotherapeutics (Inst); Agenus (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Chugai Pharma (Inst); CrystalGenomics (Inst); IDEAYA Biosciences (Inst); Inmune Bio (Inst); Kronos Bio (Inst); MBrace Therapeutics (Inst); OncoResponse (Inst); Oncternal Therapeutics (Inst); Prelude Therapeutics (Inst); Stemline Therapeutics (Inst); Takeda (Inst); Tarus Therapeutics (Inst)
 
glenn michelson
Employment - CG Pharmaceuticals
 
Lorna Liganor
Employment - CG Pharmaceuticals
 
Gene Cho
Employment - CG Pharmaceuticals
 
Sangsook Cho
Employment - CGInvites (I); CrystalGenomics (I)
Leadership - CrystalGenomics (I)
Stock and Other Ownership Interests - CGInvites (I); CrystalGenomics (I)
 
Evan Walker
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Insights Driven Research
Research Funding - CrystalGenomics, Inc. (Inst)